The social media posts have been developed to promote the UK policy action blueprint and accompanying situation analysis report. Please share the following messages via your social media channels. You are welcome to adjust the posts to best address your audience or use them as inspiration to write your own.
Please share with the hashtags #ReadyforRLT and #RLTUK.
Twitter
.@radioligand launched its policy action blueprint & situation analysis report on 9 Sep. These materials are part of a programme of work that aims to improve integration and system readiness of #RadioligandTherapy in the UK. #ReadyforRLT. Download: https://www.healthsystemreadiness.com/achieving-system-readiness-for-radioligand-therapy-in-the-uk-the-event-as-it-happened/
New types of #RadioligandTherapy are emerging, but current use is still variable. The new policy action blueprint & situation analysis report from @radioligand offer policy guidance to help ensure greater availability in the UK. #RLTUK. https://www.healthsystemreadiness.com/uk-readiness-assessment/
The recent launch of the @radioligand policy blueprint and situation analysis featured experts from @ProstateUK & @ncukcharity discussing what is needed to better plan for the wider use of #RadioligandTherapy in the UK. #ReadyforRLT. Find out more: https://www.healthsystemreadiness.com/achieving-system-readiness-for-radioligand-therapy-in-the-uk-the-event-as-it-happened/
Multidisciplinary working and training for clinicians can help improve understanding of the right time for referrals to #RadioligandTherapy. Read the @radioligand UK policy action blueprint & situation analysis report for more #ReadyforRLT #RLTUK. https://www.healthsystemreadiness.com/uk-readiness-assessment/
Better data collection and analysis are essential for improving integration of #RadioligandTherapy. Current systems do not collect adequate data to inform evidence-based decision-making. Find out more about how the UK can become #ReadyForRLT: https://www.healthsystemreadiness.com/uk-readiness-assessment/
Current integration of #RadioligandTherapy in UK cancer planning is limited. To improve this, professional societies, patient organisations & health authorities need to develop a national strategy. Read more on becoming #ReadyForRLT @radioligand: https://www.healthsystemreadiness.com/uk-readiness-assessment/
By applying their international readiness framework to the UK, @radioligand has developed a blueprint with recommendations for policymakers to create a more sustainable system for #RadioligandTherapy in the UK. #RLTUK #ReadyforRLT. Download here: https://www.healthsystemreadiness.com/uk-readiness-assessment/
Facebook
On 9 September, The Health Policy Partnership hosted the digital launch of the policy action blueprint and situation analysis report, as part of its work on health system readiness for radioligand therapy in the UK. Radioligand therapy is an innovative, targeted form of cancer treatment which can provide life-enhancing benefits where therapeutic options are limited. It is currently used for some forms of neuroendocrine cancer, but the application of radioligand therapy currently being investigated in more common cancers, it is important that we plan for its potential wider use in the UK. The blueprint and analysis report assess current barriers to integration and system readiness for radioligand therapy in the UK, and set out policy recommendations to overcome these. We need the NHS to be ready for new treatments like radioligand therapy to ensure that they are available to all people who may benefit.
Download the materials here: https://www.healthsystemreadiness.com/uk-readiness-assessment/
LinkedIn or newsletter
I joined @The Health Policy Partnership on 9 September as they launched their new work on UK readiness for radioligand therapy at an online event.
The policy action blueprint and accompanying situation analysis report assess current UK readiness for radioligand therapy and provide policy recommendations on how to better integrate the therapy into our health system.
With radioligand therapy approved for neuroendocrine tumours and new applications under investigation in prostate cancer and lymphoma, these materials offer guidance for policymakers, decision-makers, clinicians and patient advocates on how to proactively plan for potential wider use of the therapy. This can help to ensure equitable availability and seamless care for all people with cancer who may benefit from innovative therapies such as these.
Find out more and download here: https://www.healthsystemreadiness.com/uk-readiness-assessment/
